Government Relations & Regulatory
GOVERNMENT RELATIONS & REGULATORY
We help companies navigate the rules and regulations that govern their industries. Knowing how government works, we navigate opportunities that open doors for growth, innovation and profit.
Government regulations are complex. And every time the rules change, your company likely will face new challenges.
Nixon Peabody’s Government Relations & Regulatory practices offer the combined knowledge, experience and connections of more than 50 attorneys and professionals, many with backgrounds working for the agencies or legislative bodies governing our clients. Our team includes a former member of the U.S. Congress, a former U.S. Senator and attorneys who worked in various regulatory agencies, at both federal and state levels.
From our vantage point in Washington, DC, and in commercial centers across Europe and Asia, we help companies anticipate, navigate and comply with the myriad regulations that govern their industries.
Whether you need a voice in Congress or before a local administrative board, we advocate for legislative or policy changes that align with your business strategy.
Who we work with
Public and private organizations who want to stay ahead of the competition by anticipating government legislation, regulation and policy changes.
- Developers add affordable units, retail to supportive-housing projects to make them more desirable
Crain's New York Business | June 7, 2016
New York City affordable housing strategic policy advisor Deborah VanAmerongen is quoted in this article regarding recent zoning changes designed to make mixed-use developments more feasible in the state.
- Judge dismisses clay mine appeal
Finger Lakes Times | March 13, 2016
Rochester Energy & Environmental associate Amy Reichhart is mentioned as counsel for Seneca Meadows Landfill in this article about the recent appeal decision in favor of her client.
- The FDA's Priority List For 2016
Law360 | January 29, 2016
Chicago Health Care associates Erica Cribbs, Gretchen Harper and April Schweitzer co-authored this column discussing the Food and Drug Administration’s priorities for the year.